戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and 5-HT4 receptor antagonists, but not by a 5-HT3 receptor antagonist.
2  was less affected by VMN infusions with the 5-HT3 receptor antagonist.
3 nged efficacy, and acts synergistically with 5-HT3 receptor antagonists.
4 ative efficacy of the 5-hydroxytryptamine-3 (5-HT(3)) receptor antagonists.
5                Similar pretreatment with the 5-HT3 receptor antagonist 3-tropanyl-3,5-dichlorobenzoat
6                   Rats were infused with the 5-HT3 receptor antagonist, 3-tropanyl-indole-3 carbonyla
7                                Aprepitant, a 5-HT3 receptor antagonist (5HT3-RA), and dexamethasone a
8 sponses to 2-methyl-5-HT were blocked by the 5-HT(3) receptor antagonist alosetron (2 x 10(-7) M), wh
9 kg-1, i.v.), or treatment with the selective 5-HT3 receptor antagonist alosetron (30 microg kg-1, i.v
10                    Although tropisetron is a 5-HT3 receptor antagonist and an alpha7nAChR partial ago
11 1) receptor antagonist in conjunction with a 5-HT3 receptor antagonist and corticosteroid in patients
12             Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well tole
13             Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well-tole
14 isetron; 500 ng), or were coinfused with the 5-HT3 receptor antagonist and the 5-HT2A/2C receptor ago
15 rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the pr
16 d Fos-LI in the DVC of ondansetron (1 mg/kg; 5-HT3 receptor antagonist) and vehicle-treated rats foll
17               A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommen
18 combination of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone.
19 f ondansetron, a selective serotonin type-3 (5-HT3) receptor antagonist, attenuates cholecystokinin (
20 etic risk radiation therapy should receive a 5-HT(3) receptor antagonist before each fraction and for
21 by DPPIV inhibition or by cholecystokinin or 5-HT3 receptor antagonists, but was inhibited by atropin
22                     ICS205-930 (1 microM), a 5-HT3 receptor antagonist, completely blocked the 5-HT-i
23 or any highly emetic agents should receive a 5-HT(3) receptor antagonist, dexamethasone, and a neurok
24 etron (300 microg kg(-1), I.V.), a selective 5-HT(3) receptor antagonist, eliminated the afferent's r
25 ) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for the prevention of acute
26                                          The 5-HT(3) receptor antagonist granisetron (1 microM) and t
27 o 3.8 +/- 1.1 spikes s(-1)) by the selective 5-HT3 receptor antagonist granisetron.
28 -HT response was completely abolished by the 5-HT3 receptor antagonist, granisetron (0.5 mg kg-1).
29                                              5-HT(3) receptor antagonists have proved effective in su
30  wide dynamic range neurons are inhibited by 5-HT3 receptor antagonists in rats following spinal nerv
31                Treatment of ganglia with the 5-HT(3) receptor antagonist MDL 72222 (0.5 microM) durin
32             Pretreatment of ganglia with the 5-HT(3) receptor antagonist ondansetron (0.4 microm) alo
33 TS-TH-EGFP neurons, an effect blocked by the 5-HT(3) receptor antagonist ondansetron and mimicked by
34  coefficient = 1.8) that were blocked by the 5-HT3 receptor antagonist ondansetron (IC50 = 103 pM) an
35 led to do so in Tph1(-/-) colon; and (9) the 5-HT3 receptor antagonist ondansetron, which reduced CMM
36 ivity effect of intrathecal injection of the 5-HT3 receptor antagonist ondansetron.
37 rotonin and this effect was blocked with the 5-HT3-receptor antagonist ondansetron.
38           Intracranial administration of the 5-HT(3) receptor antagonist, ondansetron (OND), to the p
39                                          The 5-HT(3) receptor antagonist, ondansetron, has been shown
40 tion and predict therapeutic response to the 5-HT(3) receptor antagonist, ondansetron.
41 to treat morphine dependence, also exhibited 5-HT(3) receptor antagonist properties.
42                                              5-HT(3) receptor antagonists reduce symptoms of IBS clin
43 response to acetylcholine was blocked by the 5-HT(3) receptor antagonist renzapride with a similar IC
44 njection of tropisetron (200 microg kg-1), a 5-HT3 receptor antagonist, significantly attenuated the
45 whisking frequencies, and selective 5-HT2 or 5-HT3 receptor antagonists suppress this rhythmic firing
46    Unilateral infusion of selective 5-HT2 or 5-HT3 receptor antagonists suppresses ipsilateral whiski
47             Pretreatment of ganglia with the 5-HT(3) receptor antagonist tropisetron (0.5 microM) com
48 otetralin (DPAT; 0.1 mg/kg and 0.3 mg/kg) or 5-HT3 receptor antagonist tropisetron (0.3 mg/kg) treatm
49 fusions with 100 ng, 250 ng or 500 ng of the 5-HT3 receptor antagonist, tropisetron.
50                                          The 5-HT3 receptor "antagonists' (+)-tubocurarine and quipaz
51 urthermore, this mutation also converted the 5-HT3 receptor antagonist/very weak partial agonist, apo

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。